Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1261 to 1275 of 2183 results for guidelines

  1. Staging investigations for CPG 3 prostate cancer: What is the diagnostic accuracy of staging investigations for CPG 3 prostate cancer?

    notes(if applicable) Why the committee made the recommendation: The 2019 guideline used a 3‑tier model for risk stratification. The...

    Research recommendation
    Published
    7 January 2022

  2. What is the impact of coexisting physical health conditions on the mortality of people with complex psychosis?

    investigations before starting antipsychotic medicines recommended in the NICE guidelines on psychosis and schizophrenia in adults and...

    Research recommendation
    Published
    26 October 2020

  3. Speed of intravenous fluid resuscitation for people with acute pancreatitis:- What is the most clinically effective and cost-effective speed of administration of intravenous fluid for resuscitation in people with acute pancreatitis?

    management on outcomes in other conditionswith a pathophysiology.Current guidelines recommend using goal-directed therapy for fluid...

    Research recommendation
    Published
    17 December 2018

  4. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

    Evidence summary
    Published
    24 May 2016

  5. Haemochromatosis

    Discontinued Reference number: GID-NG10287

    NICE guideline
    Discontinued

  6. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

    Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA373

  7. Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)

    Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for malignant diseases in people for whom a reduced intensity regimen would be suitable.

    Technology appraisal guidance
    Published
    5 August 2020
    View recommendations

    Sections for TA640

  8. Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)

    Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..

    Evidence summary
    Last updated
    30 September 2014

  9. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (AMR1)

    Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.

    Antimicrobial resistance guidance
    Published
    17 August 2022
    View recommendations

    Sections for AMR1

  10. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

    Antimicrobial resistance guidance
    Published
    17 August 2022
    View recommendations

    Sections for AMR2

  11. Type 2 diabetes in adults: management - insulin therapy

    Discontinued Reference number: GID-NG10375

    NICE guideline
    Discontinued

  12. Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy (HTG337)

    Evidence-based recommendations on transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. This involves using a laser to cut out the tumour and a small amount of the healthy flesh around it.

    HealthTech guidance
    Published
    27 March 2014
    View recommendations

    Sections for HTG337

  13. Thermogard XP for therapeutic hypothermia after cardiac arrest (MIB37)

    NICE has developed a medtech innovation briefing (MIB) on Thermogard XP for therapeutic hypothermia after cardiac arrest

    Medtech innovation briefing
    Published
    9 September 2015

  14. Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

    Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.

    Technology appraisal guidance
    Published
    6 December 2023
    View recommendations

    Sections for TA935

  15. Surgical site infections: prevention and treatment - Update

    Discontinued Reference number: GID-NG10374

    NICE guideline
    Discontinued